We are live on
!
Find out more
DCM
DAFNA Capital Management Portfolio holdings
AUM
$524M
1-Year Est. Return
164.42%
This Fund
S&P 500
This Quarter
Est. Return
-12.43%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$367M
AUM Growth
-$16.9M
(-4.4%)
Cap. Flow
+$54.7M
Cap. Flow
% of AUM
14.9%
Top 10 Holdings %
Top 10 Hldgs %
47.4%
Holding
97
New
3
Increased
38
Reduced
15
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P Biotech ETF
XBI
|
+$25.8M |
| 2 |
Ascendis Pharma A/S
ASND
|
+$10.2M |
| 3 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$4.15M |
| 4 |
Adicet Bio
ACET
|
+$3.02M |
| 5 |
Alector
ALEC
|
+$2.59M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
+$2.3M |
| 2 |
LONA
LeonaBio Inc
LONA
|
+$2.17M |
| 3 |
Cogent Biosciences
COGT
|
+$1.67M |
| 4 |
Immunocore
IMCR
|
+$1.61M |
| 5 |
NTUS
Natus Medical Inc
NTUS
|
+$1.49M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 82.89% |
| 2 | Miscellaneous | 17.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
State Street SPDR S&P Biotech ETF
XBI
$11.3B
| $45.5M | 12.41% |
613,000
+343,500
| +127% | +$25.8M |
|
2
Stereotaxis
STXS
$145M
| $25.2M | 6.86% |
13,680,554
| – | – |
|
|
BHVN
3
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $16M | 4.37% |
110,100
+32,500
| +42% | +$4.15M |
|
|
4
Adicet Bio
ACET
$84.8M
| $13.7M | 3.72% |
58,485
+13,743
| +31% | +$3.02M |
|
5
Fate Therapeutics
FATE
$291M
| $13.7M | 3.72% |
550,940
+50,010
| +10% | +$1.38M |
|
6
Xenon Pharmaceuticals
XENE
$5.81B
| $13.3M | 3.64% |
438,623
+58,460
| +15% | +$1.77M |
|
|
BPMC
7
DELISTED
Blueprint Medicines
BPMC
| $13.2M | 3.6% |
261,280
+15,000
| +6% | +$879K |
|
|
8
Ascendis Pharma A/S
ASND
$16.3B
| $12.9M | 3.53% |
139,212
+108,600
| +355% | +$10.2M |
|
9
iShares Biotechnology ETF
IBB
$10.5B
| $12.1M | 3.29% |
102,500
| – | – |
|
10
Cytokinetics
CYTK
$10B
| $8.31M | 2.26% |
211,495
| – | – |
|
11
Neurocrine Biosciences
NBIX
$15.7B
| $8.06M | 2.2% |
82,655
-1,000
| -1% | -$92.3K |
|
|
KRTX
12
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $7.85M | 2.14% |
62,053
-20,000
| -24% | -$2.3M |
|
13
IDEAYA Biosciences
IDYA
$3.87B
| $7.57M | 2.06% |
548,561
+58,500
| +12% | +$651K |
|
14
Nurix Therapeutics
NRIX
$2.72B
| $7.18M | 1.96% |
566,695
+23,351
| +4% | +$265K |
|
15
Syndax Pharmaceuticals
SNDX
$1.74B
| $7.14M | 1.95% |
370,987
-1,000
| -0.3% | -$16.7K |
|
|
MRUS
16
DELISTED
Merus
MRUS
| $5.95M | 1.62% |
262,891
+27,902
| +12% | +$583K |
|
17
Revolution Medicines
RVMD
$44.6B
| $5.84M | 1.59% |
299,785
+67,684
| +29% | +$1.32M |
|
|
SAGE
18
DELISTED
Sage Therapeutics
SAGE
| $5.82M | 1.59% |
180,306
| – | – |
|
|
19
Alector
ALEC
$261M
| $5.61M | 1.53% |
552,438
+259,691
| +89% | +$2.59M |
|
20
Edgewise Therapeutics
EWTX
$4.64B
| $5.54M | 1.51% |
695,959
+339,209
| +95% | +$2.56M |
|
21
DexCom
DXCM
$34.3B
| $5.41M | 1.47% |
72,552
| – | – |
|
|
MRTX
22
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $5.34M | 1.46% |
79,600
+36,900
| +86% | +$2.35M |
|
|
CBAY
23
DELISTED
Cymabay Therapeutics
CBAY
| $5.27M | 1.44% |
1,787,569
+95,000
| +6% | +$227K |
|
24
Arcus Biosciences
RCUS
$3.72B
| $4.76M | 1.3% |
187,717
+42,500
| +29% | +$1.04M |
|
|
NTUS
25
DELISTED
Natus Medical Inc
NTUS
| $4.71M | 1.28% |
143,600
-47,035
| -25% | -$1.49M |
|
Similar funds
4WM
BB
A
HW
DAM
SDWIA
SCA
BHPW
DAFNA Capital Management's Q2 2022 Portfolio in Review
As of Q2 2022, DAFNA Capital Management held 97 positions worth $367M, down 4.4% from $384M the previous quarter. Its ten largest holdings account for 47% of the portfolio.
DAFNA Capital Management deployed $54.7M of net new capital in Q2 2022, opening 3 new positions and adding to 38 existing holdings. Its largest new stake was Keros Therapeutics: 39,000 shares worth $1.08M.
By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 89% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was Karuna Therapeutics, Inc. Common Stock, an estimated $2.3M trimmed.
- DAFNA Capital Management's largest Q2 2022 buy was Keros Therapeutics: 39,000 shares worth $1.08M.
- DAFNA Capital Management added most to State Street SPDR S&P Biotech ETF in Q2 2022, an estimated $25.8M increase.
- DAFNA Capital Management's biggest Q2 2022 reduction was Karuna Therapeutics, Inc. Common Stock, cutting an estimated $2.3M.
- DAFNA Capital Management fully exited LeonaBio Inc in Q2 2022, selling an estimated $2.17M.
- DAFNA Capital Management's ten largest holdings make up 47% of its $367M portfolio in Q2 2022.
- DAFNA Capital Management opened 3 new positions and closed 7 in Q2 2022.
- DAFNA Capital Management's portfolio value fell 4.4% quarter-over-quarter to $367M.
Based on DAFNA Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.